- ASSOCIATE PROFESSOR Medicine, Cardiology
Dr. Jill Kalman is the Director of the Cardiomyopathy
. She is an expert in the field of Congestive
Heart Failure and is extensively published in this area. Her primary focus in clinical investigation
in heart failure focuses on novel medical therapies, technologies and device
therapy in all stages of heart failure.
She began in the specialty of Heart Failure at Mount Sinai, and then
started and developed the Heart Failure Program at Beth Israel Medical Center
from 1998-2005. She was subsequently
as Director of the Cardiomyopathy Program and Chief of the Cardiac Service of
Tisch Hospital. In 2007, she was
recruited back to as the Director of the
Program to further develop and expand the Heart Failure and Transplant Program.
Dr. Kalman graduated from the of with honors and received her medical degree from the Mount Sinai School of Medicine. She has been dedicated to Mount Sinai, and completed her internal medicine residency and cardiology fellowship at the , including a research fellowship in heart failure and cardiac transplantation. Dr. Kalman has dedicated her career to improving the quality and quantity of life in patients with all stages of Heart Failure.
Neelagaru SB, Sanchez JE, Lau SK, Greenberg SM, Raval NY, Worley S, Nadamanee K, Merliss AD, Krueger S, Wood M, Wish M, Burkhoff D, Kalman J. Nonexcitatory, cardiac contractility modulation (CCM) electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart Rhythm 2006;.
Galvao M, Kalman J, Demarco T, Moskowitz R, Galvin C, Ghali J, Fonarow G. Gender Differences iospital Management and Outcomes in Patients with Decompensated Heart Failure: Analysis from the Acute Decompensated Heart Failure National Registry (ADHERE In-H. Journal of Cardiac Failure 2005;.
Mitchell J, Klapholz M, Meisner J, Kalman J, Steingart R, Sehhat K, LeJemtel T, Messineo F, Maurer M, Phillips R, Brown E, Katz S, Sleeper L, Varshneya N. Therapeutic Management of Patients Hospitalized for Heart Failure with Normal Systolic Function: Results of the New York Heart Failure Consortium Registry on Diastolic Dysfunction. J Am Coll Cardiol 2004; 43: 1432-1438.
Kukin ML, Mannino MM, Ocampo ON, Kalman J, Buchholz-Varley C, Freudenberger RS. Hemodynamic Comparison of Twice Daily Metoprolol Tartrate With Once Daily Metoprolol Succinate in Congestive Heart Failure. J Am Coll Cardiol 2000; 35: 45-50.
Kukin ML, Kalman J, Charney RH, Eng C, Buchholz-Varley C, Ocampo ON, Levy DK. Prospective, Randomized Comparison of Effect of Long-Term Treatment With Metoprolol or Carvedilol on Symptoms, Exercise, Ejection Fraction, and Oxidative Stress in Heart Failure. Circulation 1999; 99: 2645-2651.
Freudenberger R, Kalman J, Kukin M, Buhholz-Varley C, Ocampo O, Mannino MM. Effect of Race in the Response to Metoprolol in Patients with Congestive Heart Failure Secondary to Idiopathic Dilated or Ischemic Cardiomyopathy . 1997;.
Kukin ML, Kalman J, Ocampo O, Freudenberger R, Buchholz C, Mannino MM. Beta Blockade in Congestive Heart Failure. Persistent Adverse Haemodynamic Effects During Chronic Therapy with Subsequent Doses. Heart 1997; 78: 444-449.
Kukin ML, Kalman J, Ocampo O, Freudenberger R, Buchholz C, Mannino MM. Combined Alpha-Beta Blockade compared to Beta Blockade Alone in Congestive Heart Failure. Am J Cardiol 1996; 77: 486-491.
Kalman J, Buchholz C, Steinmetz M, Kukin ML, Gass A, Lansman S, Courtney M. Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting heart transplant. J Heart and Lung Transplantation 1995; 14: 1212-1217.
Levine B, Kalman J, Packer M, Fillet H, Mayer L. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. New England Journal of Medicine 1990; 323: 236-241.
- A Phase 1/2 Trial of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure Divided into Two Stages: Stage One Open-Label, Sequential Dose-Escalation Cohorts and Stage Two Randomized, Double-Blind, Placebo-Control, Parallel Cohorts (CUPID)
- Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure (FIX-HF)
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Kalman during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- BIOTRONIK; Boston Scientific Corporation; Visiting Nurse Service (VNS)
Scientific Advisory Board:
- Boston Scientific Corporation
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Boston Scientific Corporation
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Guggenheim Pavilion Floor 6th Room 6-178B
1190 Fifth Avenue
New York, NY 10029